Preclinical identification of AZD7762, a novel, potent and selective inhibitor of Checkpoint kinases

被引：0

作者：

Ashwell, Susan ^{[1
]}

Caleb, Benjamin L. ^{[1
]}

Deng, Chun ^{[1
]}

Green, Stephen ^{[2
]}

Grondine, Michael R. ^{[1
]}

Haye, Heather R. ^{[2
]}

Horn, Candice L. ^{[1
]}

Janetka, James W.

Liu, Dongfang ^{[1
]}

Mouchet, Elizabeth ^{[2
]}

Ready, Shannon ^{[1
]}

Rosenthal, Judith L. ^{[1
]}

Queva, Christophe ^{[1
]}

Taylor, Karen J. ^{[2
]}

Sheehy, Adam M. ^{[1
]}

Walker, Graeme E. ^{[2
]}

White, Anne M. ^{[2
]}

Zabludoff, Sonya D. ^{[1
]}

机构：

[1] AstraZeneca, Waltham, MA USA

[2] AstraZeneca, Macclesfield, Cheshire, England

来源：

MOLECULAR CANCER THERAPEUTICS | 2007年 / 6卷 / 12期

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：3411S / 3411S

页数：1

共 50 条

[31] Identification of clinical candidate, AZD8055: A potent, selective small molecule inhibitor of mTOR kinase
Pike, Kurt G.
Menear, Keith
Gomez, Sylvie
Malagu, Karine
Hummersome, Marc
Pass, Martin
Duggan, Heather
Hickson, Ian
Chresta, Christine
Davies, Barry
Martin, Niall
Smith, Graeme
ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2011, 241
[32] Discovery of a potent and selective Axl inhibitor in preclinical model
Inoue, Satoshi
Yamane, Yoshinobu
Tsukamoto, Shuntaro
Azuma, Hiroshi
Nagao, Satoshi
Murai, Norio
Nishibata, Kyoko
Fukushima, Sayo
Ichikawa, Kenji
Nakagawa, Takayuki
Sugi, Naoko Hata
Ito, Daisuke
Kato, Yu
Goto, Aya
Kakiuchi, Dai
Ueno, Takashi
Matsui, Junji
Matsushima, Tomohiro
BIOORGANIC & MEDICINAL CHEMISTRY, 2021, 39
[33] Radiosensitization of NSCLC cells to X-rays and carbon ions by the CHK1/CHK2 inhibitor AZD7762, Honokiol and Tunicamycin
Liu, Bingtao
Chen, Weiqiang
Li, Hongbin
Li, Feifei
Jin, Xiaodong
Li, Qiang
RADIATION AND ENVIRONMENTAL BIOPHYSICS, 2020, 59 (04) : 723 - 732
[34] Discovery and preclinical evaluation of a novel highly selective and potent CDK12 inhibitor
Yamakawa, Hiroko
Mizutani, Akio
Arikawa, Yasuyoshi
Ebara, Shunsuke
Satoh, Yoshihiko
Morishita, Daisuke
CANCER SCIENCE, 2023, 114 : 831 - 831
[35] PRECLINICAL CHARACTERIZATION OF THRX-113587: A NOVEL, POTENT AND SELECTIVE INHIBITOR FOR THE NOREPINEPHRINE TRANSPORTER
Shen, F.
Smith, J.
Tsuruda, P.
Stangeland, E.
McNamara, A.
Cremers, T.
Martin, W.
BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY, 2014, 115 : 141 - 141
[36] Characterization of AZD5363, an orally bioavailable, potent ATP-competitive inhibitor of AKT kinases with pharmacodynamic and antitumor activity in preclinical models
Davies, Barry R.
Luke, Richard
Dudley, Phillippa
Greenwood, Hannah
Crafter, Claire
Cosulich, Sabina
Page, Ken
Yates, James
Lane, Clare
Yu, Derek
Zhang, Jingchuan
Pass, Martin
CANCER RESEARCH, 2011, 71
[37] Chk1/2 inhibitor AZD7762 blocks the growth of preantral follicles by inducing apoptosis, suppressing proliferation, and interfering with the cell cycle in granulosa cells
Liu, Xiao-Ming
Chen, Fang
Zhang, Fan
Zhao, Jun-Zhao
HISTOLOGY AND HISTOPATHOLOGY, 2023, 38 (07) : 779 - 786
[38] β-hydroxyisovalerylshikonin is a novel and potent inhibitor of protein tyrosine kinases
Hashimoto, S
Xu, Y
Masuda, Y
Aiuchi, T
Nakajo, S
Uehara, Y
Shibuya, M
Yamori, T
Nakaya, K
JAPANESE JOURNAL OF CANCER RESEARCH, 2002, 93 (08): : 944 - 951
[39] Discovery and preclinical evaluation of a novel highly selective and potent CDK12 inhibitor.
Yamakawa, Hiroko
Mizutani, Akio
Arikawa, Yasuyoshi
Ebara, Shunsuke
Satoh, Yoshihiko
Morishita, Daisuke
CANCER RESEARCH, 2022, 82 (12)
[40] Preclinical development of a selective, potent small molecule ALK inhibitor
Lovly, Christine M.
de Stanchina, Elisa
Liang, Chris
Pao, William
CANCER RESEARCH, 2010, 70

← 1 2 3 4 5 →